Discover trends, market shifts, and competitive outlooks for the daratumumab or darzalex global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Milestones in the Daratumumab Or Darzalex Market’s Growth Trajectory From 2025 To 2034?

The market for daratumumab, also known as darzalex, has experienced significant growth in recent years. The size of the market is projected to increase from $5,093.04 million in 2024 to $5,618.30 million in 2025, representing a compound annual growth rate (CAGR) of 10.3%. The progression observed in the historical period is due to factors such as the implementation of numerous research avenues, the enhancing viability of biomanufacturing operations, the rising utilization of monoclonal antibodies, an increase in strategic initiatives, and heightened production of mAbs.

The market size for daratumumab or darzalex is projected to witness a significant expansion in the coming years. It is projected to attain a valuation of $8,189.36 million in 2029, with a compound annual growth rate (CAGR) of 10.0%. The enhancement in this market during the predicted period can be credited to factors such as the mounting clinical proof, growing utilisation in early treatment stages, surging need for biologics, escalated patient awareness levels, increasing cases of blood cancer, and growing occurrences of chronic disorders. Key trends for the prediction period encompass technological evolution, the launch of new products, product and/or service offerings, collaborations, mergers and acquisitions, progress in radiation technologies, and partnerships.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Daratumumab Or Darzalex Market?

The increasing occurrence of bone marrow cancer is anticipated to boost the expansion of the daratumumab or darzalex market in the future. Cancers like multiple myeloma and leukemia, which start in the bone marrow and disrupt normal bodily function through abnormal blood cell production, are known as bone marrow cancers. The spike in bone marrow cancer cases is connected to factors like an aging population, enhanced detection techniques, and contributory elements like environmental effects, lifestyle decisions, and genetic susceptibilities. Daratumumab (Darzalex) is effective in treating multiple myeloma, a bone marrow cancer type, by targeting and eliminating abnormal plasma cells in the bone marrow. For instance, the American Cancer Society predicted 89,190 lymphoma cases in January 2024 compared to 89,010 in 2022, and 35,780 myeloma cases compared to 34,470 in 2022. Consequently, the increase in bone marrow cancer incidence is spurring the daratumumab or darzalex market’s growth. The daratumumab or darzalex market’s expansion is also expected to be fuelled by the growing acceptance of biologics and targeted therapies. These specialized treatments employ drugs or other substances to specifically identify and combat molecules crucial to cancer or other diseases’ growth and survival. Increased pervasiveness of chronic diseases and advancements in precision medicine, leading to more customized and effective treatments, are prompting the uptake of targeted therapies and biologics. Daratumumab is used in targeted therapies due to its specific effect on CD38, a protein highly present on the surface of malignant plasma cells in multiple myeloma. For example, according to the Advanced Therapy Treatment Centers (ATTC), annual investments in advanced therapies spiked by 31% in 2022, with the UK accounting for 14% of all worldwide commercial ATMP clinical trials. As such, the growing acceptance of targeted therapies and biologics is propelling the daratumumab or darzalex market’s growth.

Which Primary Segments of the Daratumumab Or Darzalex Market Are Driving Growth and Industry Transformations?

The daratumumab or darzalexmarket covered in this report is segmented –

1) By Drug Type: 100Mg Injection; 400Mg Injection

2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels

3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp

Which Regions Are Key Players in the Growth of the Daratumumab Or Darzalex Market?

North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Daratumumab Or Darzalex Market?

A significant trend observed in the daratumumab or darzalex market concerns a move towards adopting early intervention solutions in oncology treatments, such as combination therapies, to improve the treatment effectiveness of multiple myeloma and other forms of cancer. Combination therapies denote treatment plans that employ more than one therapeutic agent, each with different modes of operation. These therapies often operate synergistically, enhancing effectivity, decreasing resistance, and augmenting patient outcomes, potentially lessening the adverse effects contrasted with monotherapy. For example, Johnson & Johnson, a pharmaceutical firm based in the US, earned U.S. FDA approval in July 2024 for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to use in conjugation with bortezomib, lenalidomide, and dexamethasone (D-VRd) as an induction and consolidation treatment in patients recently diagnosed with multiple myeloma (NDMM) and deemed eligible for autologous stem cell transplant (ASCT). This new approval opens up a new quadruplet therapy option from the point of diagnosis, potentially enhancing patient outcomes.

View the full report here:

https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

What Parameters Are Used to Define the Daratumumab Or Darzalex Market?

Daratumumab, or darzalex, refers to a monoclonal antibody used as a medication in the treatment of certain cancers, particularly multiple myelomas. It is designed to target and bind to CD38, a protein that is highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19896

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model